Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;49(11):10667-10676.
doi: 10.1007/s11033-022-07668-8. Epub 2022 Jun 21.

CircRNAs: novel therapeutic targets in multiple myeloma

Affiliations
Review

CircRNAs: novel therapeutic targets in multiple myeloma

Xinyi Zhou et al. Mol Biol Rep. 2022 Nov.

Abstract

Background: Circular RNA (circRNA) is a type of non-coding RNA that has recently attracted the attention of researchers. Multiple myeloma (MM) is a hematological malignancy with a dismal prognosis that indicates a pressing need for better treatment alternatives, particularly in terms of biological indicators. According to recent research findings, the presence of circRNA is also closely related to the incidence and progression of malignant hemopathy. There have been, however, only a few investigations of circRNA in MM.

Material and methods: This review will be on the biological properties and functions of circRNA in MM and a discussion of the clinical utility of circRNA in the diagnosis, prognosis, and treatment of MM.

Conclusions: CircRNA is involved in gene transcription, translation, and epigenetic modification as well as the regulation of cancer cell proliferation, invasion, and metastasis, and hence, promotes or inhibits the occurrence and progression of MM. Therefore, circRNA holds promise as a potential future MM biomarker.

Keywords: Clinical utility; Multiple myeloma; circRNA.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Moreau P et al (2013) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi133-7 - PubMed - DOI
    1. Rajkumar SV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-48 - PubMed - DOI
    1. Derman BA, Kosuri S, Jakubowiak A (2022) Knowing the unknowns in high risk multiple myeloma. Blood Rev 51:100887 - PubMed - DOI
    1. Li J et al (2020) Roles of noncoding RNAs in drug resistance in multiple myeloma. J Cell Physiol 235(11):7681–7695 - PubMed - DOI
    1. Lin Z et al (2020) The role of circular RNAs in hematological malignancies. Genomics 112(6):4000–4008 - PubMed - DOI

LinkOut - more resources